ing to thrombosis before starting OCT. However this is unfeasible because of costs and because it would not eliminate the problem of self-medication. As a consequence, we have to envisage ways to limit our coagulation screening only to a limited number of women. The rationale for the proposed flow charts is based on clinical observation and on the literature (2) (3) (4) 10, 11) . There seems to be an urgent need for sure guidelines particularly in view of recent discussion, not always balanced and fair, about the alledged increased risk of venous thrombosis in women on preparations containing gestoden or desogestrel, namely the third-generation progestins (12) (13) (14) (15) (16) (17) (18) . One has to remember that regardless of the compounds, OCT is always associated with an increase in VTE episodes. Approximately one third of these women have congenital prothrombotic conditions, approximately one third have acquired predisposing conditions, and approximately one third have had OCT thrombosis without any other associated risk factors.
There are two main problems: 1) women with a positive family history of VTE, and 2) women with a personal history of VTE with or without a positive family history.
For positive family history, one has to consider an objectively documented VTE episode seen in parents and siblings of the proposita. Children should also be taken into consideration on these final grounds but this seldom occurs because of the young age of the propositae involved. We prefer to limit the search to close or first-degree relatives (namely parents, siblings and, eventually, children). In fact we think that second-degree relatives (as cousins) have little importance if any. In fact the significance of the finding could be influenced by the interference of unrelated subjects (for example by the spouse of an uncle of the proposita). Unfortunately it is often difficult to obtain sufficient information about a past VTE. Even in doubt, the case should be treated as if VTE had really occurred. Once the occurrence of a VTE in a close relative has been established, one should try to ascertain whether the episode was idiopathic or secondary ( Fig. 1 ).
An accurate medical history carried out by an expert physician and not by an intern is of prominent importance (10) . It is often very difficult to ascertain whether a VTE was idiopathic or secondary. This is particularly so for family members who cannot be directly contacted and evaluated. When the VTE described in parents or siblings appears to be idiopathic, the proposita should not start OCT even if coagulation test results are negative. The same is true in doubtful cases. The woman with a positive family history for secondary thrombosis could receive a cautious cycle of OCT for a few months after a negative coagulation study which should include at least AT, protein C, protein S, and factor V Leiden.
If an accurate family history is not available or not satisfactory, at least some tests should be carried out. In the presence of negative test results, a short cycle of OCT could be envisaged. In the presence of particular circumstances (intolerance for intrauterine device or for other anticontraceptive measures), women with minor defects (e.g., heterozygous factor V Leiden) could also start, if needed, a short cycle of OCT after a proper coagulation study to exclude other defects (18, 19) . The same is probably true for the other minor prothrombotic defect, namely the G to A 20210 prothrombotic polymorphism (20) . Needless to say, these patients should be informed about the potential enhanced risk of VTE when more than one prothrombotic condition is present.
The second problem concerns women who have had an objectively documented previous VTE episode (Fig. 2) . For an objectively docu-mented VTE episode, we confirm deep venous thrombosis with compression ultrasonography and/or by phlebography or pulmonary embolism with perfusion/ventilation scans and/or spiral computed tomography. In this case it may be easier to ascertain whether a VTE episode was idiopathic or secondary. Women with a positive history of secondary VT should undergo extensive laboratory investigation. If the secondary nature of the past VTE is confirmed and the test results are negative, a cautious initiation of OCT can be instituted. If the secondary condition of VT is doubtful, no OCT should be started regardless of test results. Women with a history of idiopathic VTE should not be treated with OCT, regardless of the results of coagulation tests and regardless of the presence or absence of a concomitant positive family history. Even the use of preparations containing low estrogen and second-generation progestins or preparations containing only a progestin have to be excluded. The patient should be duly informed of the risk of thrombosis should she decide to continue the OCT.
CONCLUSIONS
These flow charts have been established after an extensive study of women in whom VTE developed during OCT. Some authors have concluded that family history plays no important role in predicting the occurrence of thrombosis in OC-treated women but the article was flawed in the sense that it dealt with the prothrombotic defect and not with thrombosis (21) . It is clear that the two conditions are not necessarily linked. In fact several patients with congenital prothrombotic coagulation disorders may remain asymptomatic even after long-term use of OCT. This is particularly so in the case of minor clotting defects such as factor V Leiden and the G to T 20210 prothrombin polymorphism. Even in the case of antithrombin deficiency, which in this regard appears to be the most severe defect, a few patients may remain asymptomatic (8, 9) .
The flow charts we present and discuss are not intended to represent the final solution to this problem. They represent only an attempt to limit the number of VTE episodes in OCT-treated women. By excluding women with known hereditary clotting defects or known acquired conditions, we have managed to reduce the incidence of OCT-induced VTE but, probably, not to eliminate the problem. This is mainly due to the presence of still unknown clotting prothrombotic de- fects and to the difficulty in evaluating lifestyle conditions predisposing to thrombosis. Traumas, immobilization from any cause, surgery, dehydration, splints, and casts are known acquired conditions predisposing to thrombosis. The impact of each of these is often difficult to ascertain and therefore could be underevaluated. Most of these conditions may require an interruption of OCT, some may need, should the woman refuse to discontinue OC, adequate prophylaxis with low-molecular-weight heparin or other means. This is seldom done in clinical practice so women often continue to take OC medication. The recent examples of acute severe or fatal pulmonary embolism seen in women on OCT after long air travel are the typical example of what may happen (22) . Nobody should expect that even the adherence to these flow charts or to any other procedure could completely eliminate the occurrence of OCT-associated venous thrombosis. The most that can we achieve is a reduction of VTE morbidity and mortality, which, for a practicing physician already represent a great success. In fact one should never forget the natural history of VTE-it may be a short-lived, selflimited medical experience for the patients but it may also have important long-term effects (23, 24) . However a few years ago, we observed only one venous thrombosis in approximately 200 patients observed for a total of 560 patient/years of observation. In this patient, the deep vein thrombosis of the upper limb occurred after a trauma with consequent immobilization.
The present flow charts are being validated for venous thrombosis but they could probably be of some help even in the prevention of arterial thrombosis. There are many other noncoagulation-related contraindications to the use of OCT, such as hypertension, severe diabetes mellitus, liver damage, and so on. All these conditions have to be ruled out or completely evaluated. A final word of caution: it is difficult to translate epidemiologic studies in clinical practice (25) .
